Angel Qin, MD, identified the critical role of immunotherapy timing and shared decision-making in small cell lung cancer while also addressing the need for more broadly applicable treatments and personalized care.
Angel Qin, MD
Advertisement
thoracic medical oncologist and associate professor at the University of Michigan
Articles by Angel Qin, MD
Recent clinical trials like ADRIATIC and IMforte are shaping the future of small cell lung cancer (SCLC) treatment, explained Angel Qin, MD. She also emphasized the growing role of immunotherapy in adjuvant and maintenance therapies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5